Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).
Inclusion Criteria:
Exclusion Criteria:
Winston-Salem, North Carolina 27157, United States
Philadelphia, Pennsylvania 19104, United States
Pittsburgh, Pennsylvania 15243, United States
CABA, Buenos Aires C1120AAC, Argentina
CABA, Buenos Aires C1179AAB, Argentina
CABA, Buenos Aires C1204AAD, Argentina
Ciudad Autónoma de Buenos Aire, Buenos Aires 1056, Argentina
Ciudad Autónoma de Buenos Aire, Buenos Aires C1023AAB, Argentina
C.a.b.a., Ciudad Autónoma de Buenos Aire C1205AAO, Argentina